-
Ajinomoto Co., Inc. to Sell* its Entire Equity Stake in Ajinomoto Althea, a US-based Aseptic Fill/Finish CDMO (*Completed on May 1, 2025)
-
Ajinomoto Bio-Pharma Services Awarded CDMO Leadership Awards
-
Notice of Phone Outage Due to Power Interruption
-
Notice of Discontinuation of certain Products and Services
-
Leading Global CDMO Ajinomoto Bio-Pharma Services Joins CMAC as New Translation to Industry Collaborator
-
Regarding the problem with the inquiry form; resolved on July 4th.
-
Ajinomoto Bio-Pharma Services Announces the Approval of the 32nd Drug Product at their San Diego Sterile Fill Finish Site
-
Ajinomoto Bio-Pharma Services Garners Six ‘CDMO Leadership Awards,’ Further Establishing Its Industry Excellence
-
Notice Regarding Joint Research Agreement with RIBOMIC Inc.
-
Notice Regarding the Display of Consumption Tax Under Japan’s Invoice System
GeneDesign, Inc. – Osaka Site
-
Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
-
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line